Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.91 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.91 |
| ▸ | HTR1A | P08908 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5459957 | 1.00 | ADRA1D (0.91) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL5597266 | 0.95 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9193925 | 0.90 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9200004 | 0.90 | ADRA1A (0.90) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9194060 | 0.90 | ADRA1A (0.89) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL9316958 | 0.89 | ADRA1A (0.88) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL9317007 | 0.88 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9201007 | 0.86 | ADRA1A (0.82) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL9274801 | 0.86 | ADRA1A (0.79) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9199195 | 0.85 | ADRA1D (0.81) | ADRA1DADRA1AADRA1BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| US-5164397-A | Hypotensive | SYNTHELABO (FR) | 1992-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | DRD2 435/4885HTR2A 462/4885ADRA1D 7/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | DRD2 863/4885HTR2A 311/4885ADRA1D 10/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | DRD2 561/4885HTR2A 472/4885ADRA1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.